Wexford-based COEPTIS, a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, recently closed on an additional $5.7 million in its final Series A Preferred Offering, bringing the total to $10 million.
Proceeds will be used to accelerate Coeptis’ integration of advanced artificial intelligence solutions and automation capabilities, repay outstanding obligations, strengthen the company’s balance sheet, and support general corporate purposes.
“We’re thrilled to announce the successful closure of our second Series A Preferred financing,” Brian Cogley, COEPTIS CFO, said. “This funding is pivotal as we expand our operational capabilities and enhance shareholder value through our new Technology Division. The integration of AI-driven tools, particularly from our recent acquisition of the NexGenAI Affiliates Network platform, is vital in revolutionizing our approach to marketing and operational efficiencies in the highly regulated biopharmaceutical sector.”
Series A Preferred financing is convertible into shares of the company’s common stock at $8 per share, subject to limitations. Investors also received an aggregate 15 percent equity interest in COEPTIS’s new subsidiaries, SNAP Biosciences and GEAR Therapeutics.
CJC Investment Trust led this round of financing. Christopher Calise, a COEPTIS board of directors member, controls the company.
COEPTIS closed on $4.3 million in June 2024.